Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B

Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonacog gamma (BAX 326, Rixubis ® [Baxalta US Inc., a T...

Full description

Bibliographic Details
Main Authors: Jerzy Windyga MD, PhD, Margarita Timofeeva MD, Oleksandra Stasyshyn MD, PhD, Vasily Mamonov MD, PhD, José Luis Lamas Castellanos MD, Toshko Lissitchkov MD, PhD, Krzysztof Chojnowski MD, PhD, Miranda Chapman BSc, Borislava G. Pavlova PhD, Srilatha Tangada PhD
Format: Article
Language:English
Published: SAGE Publishing 2020-08-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/1076029620946839

Internet

https://doi.org/10.1177/1076029620946839

Similar Items